ATAGI and the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) have released a joint statement surrounding the administration of COVID-19 AstraZeneca and 血栓形成伴血小板减少症候群 (TTS).

Following close monitoring of local and international data it has been noted that the risk of TTS is not likely to be increased in people who:

  • Have a history of blood clots in typical sites
  • Have an increased clotting tendency that is not immune mediated
  • Have a family history of blood clots
  • Have a history of ischaemic heart disease
  • Currently have or has a history of thrombocytopenia
  • Are receiving anticoagulation therapy

Comirnaty™ is the preferred COVID-19 vaccine for people who:

  • Have a history of idiopathic splanchnic vein thrombosis
  • Have a history of antiphospholipid syndrome with thrombosis
  • Individuals < 50 years of age
  • Have a history of cerebral venous sinus thrombosis (CVST)
  • Have a history of heparin-induced thrombocytopenia (HIT)
  • Have a contraindication to COVID-19 AstraZeneca (including anaphylaxis to a previous dose or anaphylaxis to a component of COVID-19 AstraZeneca, TTS occurring after a dose of COVID-19 AstraZeneca or other serious adverse event following receipt of COVID-19 AstraZeneca)


Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca